4-N-cyclohexyl-6-methyl-2-N-[(1R)-1-phenylethyl]pyrimidine-2,4-diamine | 1207424-48-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-N-cyclohexyl-6-methyl-2-N-[(1R)-1-phenylethyl]pyrimidine-2,4-diamine
• CAS: 1207424-48-3
• 化学式: C₁₉H₂₆N₄
• 分子量: 310.442
• InChiKey: XOVKFJLQIHTQCJ-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  49.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  R(+)-alpha-甲基苄胺 、 2-chloro-4-cyclohexylamino-6-methylpyrimidine 以 1,4-二氧六环 为溶剂， 以62%的产率得到4-N-cyclohexyl-6-methyl-2-N-[(1R)-1-phenylethyl]pyrimidine-2,4-diamine
  参考文献：
  名称：

  Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines

  摘要：

  Two sets of diaminopyrimidines, totalling 45 compounds, were synthesized and assayed against Plasmodium falciparum. The SAR was relatively shallow, with only the presence of a 2-(pyrrolidin-1-yl)ethyl group at R-2 significantly affecting activity. A subsequent series addressed high Log D values by introducing more polar side groups, with the most active compounds possessing diazepine and N-benzyl-4-aminopiperidyl groups at R-1/R-2. A final series attempted to address high in vitro microsomal clearance by replacing the C6-Me group with CF3, however antiplasmodial activity decreased without any improvement in clearance. The C6-CF3 group decreased hERG inhibition, probably as a result of decreased amine basicity at C2/C4. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.133

文献信息

• [EN] CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE<br/>[FR] CERTAINES AMINO-PYRIDAZINES, COMPOSITIONS CONTENANT CES DERNIÈRES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CYTOKINETICS INC

  公开号：WO2011133888A1

  公开（公告）日：2011-10-27

  Provided are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

  提供的是公式(I)的化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、X和m的定义如本文所述。还提供了一种药学上可接受的组合物，包括公式I的化合物或其药学上可接受的盐。还提供了使用公式I的化合物或其药学上可接受的盐的方法。
• AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS
  申请人：Cytokinetics, Inc.

  公开号：US20210045997A1

  公开（公告）日：2021-02-18

  Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

  提供的是公式I的化合物：或其药学上可接受的盐，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，X和m的定义如此。还提供了一种药学上可接受的组合物，包括公式I的化合物或其药学上可接受的盐。还提供了使用公式I的化合物或其药学上可接受的盐的方法。
• CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE
  申请人：Yang Zhe

  公开号：US20140206709A1

  公开（公告）日：2014-07-24

  Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

  提供了公式I的化合物：或其药学上可接受的盐，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，X和m的定义如本文所述。还提供了包含公式I化合物或其药学上可接受的盐的药学上可接受的组合物。还提供了使用公式I化合物或其药学上可接受的盐的方法。
• Amino-pyrimidine skeletal muscle modulators
  申请人：CYTOKINETICS, INC.

  公开号：US10272030B2

  公开（公告）日：2019-04-30

  Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

  提供的是式 I 的化合物： 或其药学上可接受的盐，其中 R1、R2、R3、R4、R5、R6、R7、R8、R9、X 和 m 如本文所定义。 还提供了一种药学上可接受的组合物，包含式 I 的化合物或其药学上可接受的盐。 还提供了使用式I化合物或其药学上可接受的盐的方法。
• US8962632B2
  申请人：——

  公开号：US8962632B2

  公开（公告）日：2015-02-24